2Watanabe A, Maehara Y, Okuyama T, Kakeji Y, Korenaga D,Sugimachi K. Gastric carcinoma with pyloric stenosis. Surgery 1998; 12- 330-334.
3Wu Cw, Wang SR, Chao MF, Wu TC. Serum Interleukin6 levels reflect disease status of gastric cancer. Am J Gastroentrol 1996; 91:1417-1422.
4Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet 2001; 357:539-545.
5Salgado R, Vermeulen PB, Benoy I, Weyjens R, Huget P, Van Marck E, Dirix LY. Platelet number and interleukin6 correlate with VEGF but not with bFGF serum levels of advanced cancer patients. Br J Cancer 1999; 80:892-897.
6Salgado R, Benoy I, Weytjens R, Vermeulen PB, Dirix LY. Serum vascular endothelial growth factor load and interleukin-6 in cancer patients-reply. Br J Cancer 2000; 82:1896.
7Zhang G J, Adachi I. Serum interleukin6 levels correlate to tumor progression and prognosis in metastatic breast carcinoma.Anticancer Res 1999; 19:1427-1432.
8Everett SM, Singh R, Leuratti C, White KL, Neville P, Greenwood D, Marnett LJ, Schorah CJ, Forman D, Shuker D, Axon AT. A Levels of Malondialdehyde-Deoxyguanosine in the Gastric mucosa: relationship with lipid peroxidation, ascorbic acid,and Helicobacter pylori. Cancer Epidemiol Biomarkers Prev 2001; 10-369-376.
9Assreuy J, Cunha FQ, Liew FY, Moncada S. Feedback inhibition of nitric oxide synthase activity by nitric oxide. Br J Pharmacol 1993; 108:833-837.
10DeRojas-Walker T, Tamir S, Ji H, Wishnok JS, Tannenbaum SR.Nitric oxide induces oxidative damage in addition to deamination in macrophage DNA. Chem Res Toxicol 1995; 8:473-477.
